Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04825743 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
A Phase 3 study of ST-elevation Myocardial Infarction (STEMI), sponsored by CeleCor Therapeutics.
- Active
- Registry status
- Phase 3
- Development phase
- 2,463
- Enrollment target
- 20
- Study locations
NCT04825743 is a Phase 3 study of ST-elevation Myocardial Infarction (STEMI) that is active but no longer recruiting, run by CeleCor Therapeutics. The registered enrollment target is 2,463 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT04825743, a Phase 3 study of ST-elevation Myocardial Infarction (STEMI), is active but no longer recruiting, sponsored by CeleCor Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,463 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study. Subjects with STEMI will be enrolled in the ambulance if they meet all eligibility criteria. These subjects will be evaluated by (para)medics who transport the subjects to the participating hospitals in Europe and North America. Hospitals and ambulance services with experience in ambulance studies will be selected. Each subject will receive a single subcutaneous injection containing either Disaggpro(tm) zalunfiban Dose 1 (0.110 mg/kg) or Disaggpro(tm) zalunfiban Dose 2 (0.130 mg/kg) or placebo
Conditions Studied
Interventions
- DRUG Placebo
- DRUG zalunfiban
Study Locations (20)
Other
- University of Alberta - Edmonton
- St. Anne's University hospital - Brno
- University Hospital Brno - Brno
- European Hosital de Paris - GVM Care & Research (La Roseraie) - Aubervilliers
- Hospital Ambroise Pare - Boulogne-Billancourt
- Henri Mondor University Hospital - Créteil
- Grenoble Alpes University Hospital - Grenoble
- University Hospital of Marseille - La Timone Hospital - Marseille
- André Grégoire Hospital - GHT GPNE - Montreuil
- Bichat-Claude Bernard Hospital - Paris
- Hôpital Cochin - Paris
- Lariboisière Hospital AP-HP - Paris
- University Hospital De La Pitié-Salpêtrière - Paris
- Regional University Hospital of Rennes - Hospital Ponchaillou - Rennes
- Semmelweis University Heart and Vascular Center - Budapest
Texas
- UT Southwestern Medical Center - Dallas
- Baylor College of Medicine - Houston
Alaska
- Providence Alaska Medical Center - Anchorage
Michigan
- Corewell Health William Beaumont University Hospital - Royal Oak
Missouri
- Washington University - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,463 participants |
| Start Date | 2021-04-24 |
| Est. Completion | 2026-05-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04825743
The ClinicalTrials.gov registry entry for NCT04825743 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 2,463 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CeleCor Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with ST-elevation Myocardial Infarction (STEMI) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04825743 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Texas, Alaska.
Frequently Asked Questions
What is clinical trial NCT04825743 about?
NCT04825743 is a clinical study titled "A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI". This is a Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study. Subjects with STEMI will be enrolled in the ambulance if they meet all eligibility criteria. These subjects will be evaluated by (para)medics who transport the subjects to the participating hospi...
What is the current status of trial NCT04825743?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 2,463 participants. The study started on 2021-04-24. Estimated completion is 2026-05-13.
What conditions does trial NCT04825743 study?
This clinical trial studies the following conditions: ST-elevation Myocardial Infarction (STEMI).
What interventions are being tested in trial NCT04825743?
The interventions under investigation include: Placebo (DRUG), zalunfiban (DRUG).
Who is sponsoring clinical trial NCT04825743?
This trial is sponsored by CeleCor Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04825743 being conducted?
This trial has 20 study locations across Alaska, Michigan, Missouri, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.